International Conference on Translational Research ICTR 2003 Conference Summary: Marshalling resources in a complex time

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 2, 2004, Pages 307-319

  Coleman, C Norman ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biological models; Imaging; Molecular targets; Radiation biology; Radiation oncology; Translational research

Indexed keywords

BIOCHEMISTRY; HEALTH CARE; IMMUNOLOGY; PHOTONS; RADIOISOTOPES; RADIOTHERAPY; TUMORS;

BRACHYTHERAPY;

ONCOLOGY;

AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CISPLATIN; CYTOTOXIC AGENT; GELDANAMYCIN; IBRITUMOMAB TIUXETAN; KU ANTIGEN; METAL CHELATE; NITROXIDE DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRIMIDINE DERIVATIVE; RADIOISOTOPE; RADIOPROTECTIVE AGENT; RADIOSENSITIZING AGENT; TIRAPAZAMINE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR TARGETING AGENT;

BIOLOGICAL MODEL; BIOLOGICAL THERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CARCINOMA; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DNA REPAIR; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG UPTAKE; GENE THERAPY; HEAD CANCER; HUMAN; IMAGING; MATHEMATICAL MODEL; MOLECULAR BIOLOGY; NECK CANCER; PARTICLE RADIATION; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION FIELD; RADIATION INJURY; RADIATION RESPONSE; RADIODIAGNOSIS; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR LOCALIZATION; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0942300645     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.056     Document Type: Conference Paper

References (58)

1. Coleman C.N. International Conference on Translational Research and Preclinical Strategies in Radio-Oncology (ICTR) - conference summary. Int J Radiat Oncol Biol Phys. 49:2001;301-309.
2. Stix G. Little big science Nanotechnology . Sci Am. 285:2001;32-37.
3. Patel HR, Mirsadraee S, Emberton M. The patient's dilemma: Prostate cancer treatment choices. J Urol 2003;169:828-833.
4. Coleman CN. Linking radiation oncology and imaging through molecular biology Or: Now that therapy and diagnosis have separated, it's time to get together again! Annual RSNA Radiation Oncology Oration, 2002. Radiology, 2003;228:29-35.
5. Freeman H.P. Culture, poverty, and cancer. Asian Am Pac Isl J Health. 6:1998;410-413.
6. Bernier J., Fuks Z. ICTR 2003 Advances in translational radiation oncology: From molecular signaling to cancer cure . Int J Radiat Oncol Biol Phys. 55:2003;437-555.
7. Jackson S.P. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 23:2002;687-696.
8. Essers J, Van Steeg H, de Wit J, et al. Homologous and non-homologous recombination differentially affect DNA damage repair in mice. EMBO J 2000;19:1703-1710.
9. Tauchi H, Matsuura S, Kobayashi J, et al. Nijmegen breakage syndrome gene, NBSI and molecular links to factors for genome stability. Oncogene 2002;21:8967-8980.
10. Donoho G, Brenneman MA, Cui TX, et al. Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability and reduced life span in mice. Genes Chromosomes Cancer 2003;36:317-331.
11. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:2003;499-506.
12. Hannon G.J. RNA interference. Nature. 418:2002;244-251.
13. Joyce G.F. The antiquity of RNA-based evolution. Nature. 418:2002;214-221.
14. Dennis C. The brave new world of RNA. Nature. 418:2002;122-124.
15. Matzke M., Matzke A.J., Kooter J.M. RNA Guiding gene silencing . Science. 293:2001;1080-1083.
16. Opalinska J.B., Gewirtz A.M. Nucleic-acid therapeutics Basic principles and recent applications . Nat Rev Drug Discov. 1:2002;503-514.
17. Kastan M.B., Zambetti G.P. Parc-ing p53 in the cytoplasm. Cell. 112:2003;1-2.
18. Fang S, Jensen P, Ludwig RL, et al. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000;275:8945-8951.
19. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2 and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-513.
20. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(4 Suppl.):S55-S61.
21. Weissleder R., Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 9:2003;123-128.
22. Rice J.C., Allis C.D. Code of silence. Nature. 414:2001;258-261.
23. Turner B.M. Cellular memory and the histone code. Cell. 111:2002;285-291.
24. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
25. Rugo R.E., Secretan M.B., Schiestl R.H. X radiation causes a persistent induction of reactive oxygen species and a delayed reinduction of TP53 in normal human diploid fibroblasts. Radiat Res. 158:2002;210-219.
26. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
27. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867.
28. Ling OC, Hamm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-560.
29. von Eschenbach AC for the S.O.T. NCI. The Nation's Investment in Cancer Research. NIH Publication No. 03-4373, 2002.
30. Krishna MC, English S, Yamada K, et al. Overhauser enhanced magnetic resonance imaging for tumor oximetry: Coregistration of tumor anatomy and tissue oxygen concentration. Proc Natl Acad Sci USA 2002;99:2216-2221.
31. Krishna MC, Subramanian S, Kappuswamy A, et al. Magnetic resonance imaging for in vivo assessment of tissue oxygen concentration. Semin Radiat Oncol 2001;11:58-69.
32. Lal A, Peters H, St. Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001;93:1337-1343.
33. Coleman C.N., Mitchell J.B., Camphausen K. Tumor hypoxia Chicken, egg, or a piece of the farm? J Clin Oncol. 20:2002;610-615.
34. Weissleder R. Scaling down imaging Molecular mapping of cancer in mice . Nat Rev Cancer. 2:2002;11-18.
35. Burger KN, Statthorst RW, de Vijder HC, et al. Nanocapsules: Lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 2002;8:81-84.
36. Couzin J. Cancer research Nanoparticles cut tumors' supply lines . Science. 296:2002;2314-2315.
37. Brown J.M., Wouters B.G. Apoptosis p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
38. Brahme A. Individualizing cancer treatment Biological optimization models in treatment planning and delivery . Int J Radiat Oncol Biol Phys. 49:2001;327-337.
39. Peters L., McKay M. Predictive assays Will they ever have a role in the clinic? Int J Radiat Oncol Biol Phys. 49:2001;501-504.
40. Russell N.S., Begg A.C. Editorial - radiotherapy and oncology 2002 Predictive assays for normal tissue damage . Radiother Oncol. 64:2002;125-129.
41. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2:2002;727-739.
42. Man S., Bocci G., Francia G., et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62:2002;2731-2735.
43. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
44. Shi W., Dong M.M., Shi W.J., et al. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol. 66:2003;1-9.
45. Siemann D.W., Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol. 13:2003;53-61.
46. Li C.Y., Shan S., Cao Y., et al. Role of incipient angiogenesis in cancer metastasis. Cancer Metasta Rev. 19:2000;7-11.
47. Paris F., Fuks Z., Kang A., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 293:2001;293-297.
48. Gupta R.A., Tejada L.V., Tong B.J., et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63:2003;906-911.
49. Palayoor S.T., Bump E.A., Galderwood S.K., et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res. 4:1998;763-771.
50. Stone H.B., McBride W.H., Coleman C.N. Modifying normal tissue damage postirradiation Report of a workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland, September 6-8, 2000 . Radiat Res. 157:2002;204-223.
51. Verellen D., Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother Oncol. 53:1999;199-203.
52. Meeks S.L., Paulino A.C., Pennington E.C., et al. In vivo determination of extra-target doses received from serial tomotherapy. Radiother Oncol. 63:2002;217-222.
53. Khan M.A., van Dyk J., Yeung I.W., et al. Partial volume rat lung irradiation Assessment of early DNA damage in different lung regions and effect of radical scavengers . Radiother Oncol. 66:2003;95-102.
54. Grdina D.J., Murley J.S., Kataoka Y. Radioprotectants Current status and new directions . Oncology. 63:(Suppl, 2):2002;2-10.
55. Mitchell JB, Krishna MC. Nitroxides as radiation protectors. Mil Med 2002;167(2 Suppl):49-50.
56. Purdy J.A. Dose-volume specification New challenges with intensity-modulated radiation therapy . Semin Radiat Oncol. 12:2002;199-209.
57. Coleman C.N. Young Investigators Workshop - Radiation Research Program, Radiation Oncology Sciences Program, National Cancer Institute, NIH, August 1-2, 2000. Int J Radiat Oncol Biol Phys. 49:2001;1505-1516.
58. Coleman C.N., Blakely W.F., Fike J.R., et al. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res. 159:2003;812-834.